Greater China
Testing China: Openings in a downturn?
With the health of China's economy deteriorating, private equity investors have every reason to expect to see plenty of opportunities to deploy capital in 2019
Tencent-backed Weimob surges 14% on Hong Kong debut
Weimob, a Shanghai-based provider of marketing and cloud services to online merchants that is backed by Tencent Holdings and several private equity firms, has surged 14% on its first day of trading on the Hong Kong Stock Exchange.
Carlyle makes six promotions in Asia
The Carlyle Group has promoted Ling Yang, a managing director in the firm’s Shanghai office, to partner. Yang is one of 60 senior promotions announced by Carlyle worldwide, including six in the Asia buyout team.
Fund focus: Lightspeed ends 2018 with a flourish
Lightspeed China Partners took just three months to raise $560 million for its fourth US dollar fund, which includes a $200 million sidecar for follow-on investments
Chinese eye hospital chain Chaoju raises $59m
Chinese eye hospital chain operator Chaoju Ophthalmology has raised RMB400 million ($59 million) in a Series B round of funding backed by Orchid Asia Group and River Head Capital.
Ping An, CITIC invest China's Airdoc
Ping An Insurance and CITIC Group have made a Series B investment of undisclosed size in Airdoc, a Chinese medical services company that uses artificial intelligence (AI).
China’s Yimidida raises $266m Series D
Chinese logistics firm Yimidida has raised RMB1.8 billion ($266.1 million) in a Series D round of funding led by Boyu Capital.
US, China-based Apollomics raises $100m Series B
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
Chinese cancer database provider Medbanks raises $59m
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Sequoia, HighLight lead $80m round for China's BrightGene
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
TPG, CICC establish dual currency China investment platform
TPG Capital and CICC Capital, the private equity arm of China International Capital Corporation (CICC), have agreed to establish a joint platform that will make investments in US dollars and renminbi.
AVCJ Awards 2018: Firm of the Year - Large Cap: Bain Capital
Bain Capital’s recent investment and exit activity underlines the importance of cross-border competencies. The GP also won the awards for Deal of the Year - Large Cap and Exit of the Year - Large Cap
Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
China’s Zhiyun Health nets $100m Series C round
Chinese online healthcare services provider Zhiyun Health has raised $100 million in a Series C round of funding across two tranches.
China wearables player Nreal confirms $15m Series A
Nreal, a China-based company that makes advanced virtual reality glasses that resemble normal sunglasses, has raised $15 million in Series A funding from investors including Shunwei Capital.
China's K2VC severs ties with spin-out over IP breach
Chinese early-stage investor China Renaissance K2 Ventures (K2VC) has publicly attacked Next Capital - a spin-out from the venture capital firm - for allegedly stealing confidential information.
Venture capital: The battle to be different
VC fundraising has been on a roll in Asia as managers raise larger sums to address fast-growing investment opportunities. GPs must consider what – and how much – makes them stand out from the crowd
Qihoo B2B software spin-out raises $132m
360 Enterprise Security, a Chinese B2B internet security software provider that spun-out from Qihoo 360, has closed a Series B round of funding worth RMB900 million ($132 million), achieving a valuation of RMB20.6 billion.
China Everbright closes global fund at $539m
China Everbright has reached a final close of $539 million on its cross-border investment fund, with the commitments coming from corporate investors, family offices, and fund-of-funds.
China's Miaoshou Doctor raises $72.8m
China-based healthcare care services provider Miaoshou Doctor has raised RMB500 million ($72.8 million) in an extended Series C round of funding led by Starquest Capital, with participation from Sequoia Capital China.
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
SenseTime backs China autonomous driving start-up WeRide
WeRide.ai, a Chinese autonomous driving technology specialist formerly known as Jingchi.ai, has raised several hundred millions of US dollars in an extended Series A round led by local artificial intelligence (AI) company SenseTime.
Shenzhen Capital hits first close on debut M&A fund
Shenzhen Capital Group has reached a first close of RMB1.8 billion ($263 million) on its debut M&A fund. The vehicle has an overall target of RMB3.6 billion.
Chinese gene therapy player raises $45m
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.
